Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

DeepDrugDiscovery identifies blood-brain barrier permeable autophagy enhancers for Alzheimer's disease.

Nature biomedical engineering·2026

Same author

C/EBPβ dictates postmenopausal FSHβ transcription and blockade of AEP/C/EBPβ pathway alleviates osteoporosis.

Bone research·2026

Same author

Diagnosis of Major Depressive Disorder Based on Multi-Granularity Brain Networks Fusion.

IEEE journal of biomedical and health informatics·2025

Same author

Oligomeric hyaluronic acid-modified liposomes effectively improved skin permeability and anti-ageing activity of ellagic acid.

Scientific reports·2025

Same author

Early-life famine exposure increases the risk of subsequent physical disability: evidence from a national population-based survey.

Frontiers in public health·2025

Same author

[Application of mixed methods systematic review in the evidence-based evaluation of acupuncture and moxibustion].

Zhen ci yan jiu = Acupuncture research·2025

Search research articles

Related Experiment Video

Updated: May 7, 2025

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Published on: May 29, 2017

Positron emission tomography tracers for synucleinopathies.

Jie Xiang¹, Zhentao Zhang², Shengxi Wu¹

¹Department of Neurobiology, Fourth Military Medical University, Xi'an, 710032, China.

Molecular Neurodegeneration

|January 5, 2025

Summary

Molecular imaging advances are crucial for diagnosing synucleinopathies like Parkinson's disease. New alpha-synuclein (α-synuclein) PET tracers show promise for clinical use, aiding drug development and disease monitoring.

Keywords:

Positron emission tomography imaging Tracer development α-synuclein

More Related Videos

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Published on: October 26, 2018

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Related Experiment Videos

Last Updated: May 7, 2025

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Published on: May 29, 2017

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Published on: October 26, 2018

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Area of Science:

Neuroscience
Radiochemistry
Pharmacology

Background:

Synucleinopathies, including Parkinson's disease, are defined by alpha-synuclein (α-synuclein) aggregation in the brain.
Distinct α-synuclein brain distribution aids in differentiating synucleinopathies, but distinguishing them from tauopathies remains challenging for clinical diagnosis and drug development.

Purpose of the Study:

To review recent advancements in molecular imaging for synucleinopathies.
To highlight promising alpha-synuclein (α-synuclein) positron emission tomography (PET) tracers for clinical diagnosis and drug efficacy assessment.

Main Methods:

Review of current literature on α-synuclein PET tracers.
Analysis of tracer characteristics, including compound structures and pre-clinical/clinical development status.

Main Results:

Significant progress in developing α-synuclein-specific PET tracers, with many in pre-clinical stages.
Some tracers with similar structures are nearing clinical application, indicating a positive trend.

Conclusions:

Molecular imaging, particularly with novel α-synuclein PET tracers, is vital for synucleinopathy diagnosis and management.
Further research is needed to overcome challenges in developing and optimizing these tracers for widespread clinical use.